Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Research and Practice in Thrombosis and Haemostasis Année : 2022

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

, , (1) , , , (2) , (3) , (4) , (5, 6) , , , (7) , (8) , (9) , , , , , (10) , (11, 12) , , (13) , (14) , (15, 7) , , , , , , , (16) , , (17) , (18)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Ingrid M. Bistervels
  • Fonction : Auteur
Roisin Bavalia
  • Fonction : Auteur
Arina J. Ten Cate-Hoek
  • Fonction : Auteur
Sebastian M. Schellong
  • Fonction : Auteur
Karina Meijer
  • Fonction : Auteur
Wim G. Boersma
  • Fonction : Auteur
Marije Ten Wolde
  • Fonction : Auteur
Susan R. Kahn
  • Fonction : Auteur
Waleed Ghanima
  • Fonction : Auteur
Karine Montaclair
  • Fonction : Auteur
Amanda Hugman
  • Fonction : Auteur
Olivier Sanchez
  • Fonction : Auteur
Simone Birocchi
  • Fonction : Auteur
Hilde S. Wik
  • Fonction : Auteur
Barbara A. Hutten
  • Fonction : Auteur
Michiel Coppens
  • Fonction : Auteur
Christiane Naue
  • Fonction : Auteur
Michael A. Grosso
  • Fonction : Auteur
Minggao Shi
  • Fonction : Auteur
Yong Lin
  • Fonction : Auteur
Isabelle Quere

Résumé

Background Postthrombotic syndrome (PTS) is a long-term complication after deep vein thrombosis (DVT) and can affect quality of life (QoL). Pathogenesis is not fully understood but inadequate anticoagulant therapy with vitamin K antagonists is a known risk factor for the development of PTS. Objectives To compare the prevalence of PTS after acute DVT and the long-term QoL following DVT between patients treated with edoxaban or warfarin. Methods We performed a long-term follow-up study in a subset of patients with DVT who participated in the Hokusai-VTE trial between 2010 and 2012 (NCT00986154). Primary outcome was the prevalence of PTS, defined by the Villalta score. The secondary outcome was QoL, assessed by validated disease-specific (VEINES-QOL) and generic health-related (SF-36) questionnaires. Results Between 2017 and 2020, 316 patients were enrolled in 26 centers in eight countries, of which 168 (53%) patients had been assigned to edoxaban and 148 (47%) to warfarin during the Hokusai-VTE trial. Clinical, demographic, and thrombus-specific characteristics were comparable for both groups. Mean (SD) time since randomization in the Hokusai-VTE trial was 7.0 (1.0) years. PTS was diagnosed in 85 (51%) patients treated with edoxaban and 62 (42%) patients treated with warfarin (adjusted odds ratio 1.6, 95% CI 1.0-2.6). Mean differences in QoL scores between treatment groups were not clinically relevant. Conclusion Contrary to our hypothesis, the prevalence of PTS tended to be higher in patients treated with edoxaban compared with warfarin. No differences in QoL were observed. Further research is warranted to unravel the role of anticoagulant therapy on development of PTS.

Dates et versions

hal-03760268 , version 1 (25-08-2022)

Identifiants

Citer

Ingrid M. Bistervels, Roisin Bavalia, Jan Beyer-Westendorf, Arina J. Ten Cate-Hoek, Sebastian M. Schellong, et al.. Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2022, 6 (5), ⟨10.1002/rth2.12748⟩. ⟨hal-03760268⟩
10 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More